Mark Schneyer
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Mark Schneyer
Mark Schneyer is recorded as CFO at Acadia Pharmaceuticals Inc (ACAD). The proxy statement of Acadia Pharmaceuticals Inc reports total compensation of $2,353,204 for Mark Schneyer in fiscal 2022, including a base salary of $467,283. Disclosed compensation is on record for 2 fiscal years. Mark Schneyer has spoken on 16 earnings calls across 1 company, most recently for Acadia Pharmaceuticals Inc on August 4, 2026.
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Acadia Pharmaceuticals Inc
Other people whose current roles at this company are on record from its filings.
- Catherine Owen Adams CEO, Board Member
- Stephen R. Biggar Chairman, Board Member
- Mark C. Schneyer CFO
- Brendan P. Teehan COO
- Austin D. Kim General Counsel
- James K. Kihara Chief Accounting Officer
- Adora Ndu Board Member
- Adora Ndu, Pharm.D., J.D. Board Member
- Daniel B. Soland Board Member
- Edmund P. Harrigan Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Acadia Pharmaceuticals Inc (ACAD) | Chief Financial Officer | $467,283 | $2,353,204 |
| 2021 | Acadia Pharmaceuticals Inc (ACAD) | Chief Financial Officer | $398,183 | $3,182,819 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.